Publish in this journal
Journal Information
Vol. 69. Issue 12.
Pages 1224-1225 (December 2016)
Download PDF
More article options
Vol. 69. Issue 12.
Pages 1224-1225 (December 2016)
Scientific letter
DOI: 10.1016/j.rec.2016.05.030
Full text access
Prospective Validation of the Redin-SCORE to Predict the Risk of Rehospitalization for Heart Failure in a Contemporary Cohort of Outpatients
Validación prospectiva del Redin-SCORE para predecir el riesgo de reingreso por insuficiencia cardiaca en una cohorte actual de pacientes ambulatorios
Andreu Ferrero-Gregori
Corresponding author

Corresponding author:
, Jesús Álvarez-García, Eduard Solé González, Sonia Mirabet Pérez, Juan Cinca, Eulalia Roig, on behalf of the investigators of the Spanish Heart Failure Network (REDINSCOR)
Departamento de Cardiología, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Universidad Autónoma de Barcelona, Barcelona, Spain
This item has received
(Daily data update)
Article information
Full Text
Download PDF
Figures (1)
Tables (1)
Table. Baseline Characteristics of the Population According to Risk of Heart Failure at 1 Year
Full Text
To the Editor,

The natural history of heart failure (HF) is marked by decompensations, which usually require hospitalization. In Spain, the number of hospital admissions for HF has increased in recent decades.1,2 In addition to the inherent cost, in-hospital mortality is also high.3 Prevention of readmission should therefore be one of the main objectives of the treatment of outpatients with HF. Most models for predicting readmission are based on data from hospitalized patients and so they do not reliably reflect the clinical condition of outpatients. Recently, our group has developed a new tool, the Redin-SCORE,4 to calculate the risk of readmission due to HF in the short- and long-term for outpatients. The score is easy to calculate and uses 6 parameters regularly monitored in patients with HF: presence of signs of left HF (paroxysmal nocturnal dyspnea, orthopnea, third heart sounds or crackles); heart rate > 70 bpm; anemia (hemoglobin < 130g/L in men and < 120g/L in women); N-terminal fraction of brain natriuretic peptide > 1000 ng/L; glomerular filtration rate < 60mL/min/1.73 m2; and dilated left atrium in the echocardiogram (> 26 mm/m2). However, one of the limitations inherent in any score is the need of validation in other populations and, in our particular case, the low incidence of events (17%) recorded in the original sample. Therefore, to extend the validity of this new risk scale, it was decided to assess its predictive and discriminatory capacity in a contemporary cohort of outpatients with heart failure.

To this end, a prospective study was undertaken with patients referred for the first time to the HF unit of our hospital between June 2012 and December 2014 (n=237). Follow-up was performed by a trained group of cardiologists and nursing staff through review of medical records and telephone calls to register data on hospitalization for HF during the following year. The discriminatory capacity was calculated using the C statistic. The calibration, slope, and intersection of the model were assessed using the Hosmer-Lemeshow goodness-of-fit test. The decision curves were analyzed to determine when application of the Redin-SCORE increased the number of true positives without increasing the number of false negatives.5,6

Of the 237 patients included, 5.4% (13 patients) required admission for HF during the first month and 29.5% (70 patients) during the first year. The main characteristics of the cohort according to the presence of events at follow-up are shown in the Table. The patients who were admitted for HF were older and a higher proportion had ischemic heart disease. They were also in a more advanced functional class. In the laboratory tests, these patients had a lower glomerular filtration rate and more frequently had anemia and elevated N-terminal fraction of brain natriuretic peptide. Mortality and need for heart transplant were also higher in these patients.


Baseline Characteristics of the Population According to Risk of Heart Failure at 1 Year

  No admission (n = 167)  Admission for HF (n = 70)  P 
Men  114 (68)  50 (71)  .630 
Age, y  65 ± 14  70 ± 11  .008 
Atrial fibrillation  60 (36)  29 (41)  .425 
Ischemic origin  44 (26)  32 (46)  .004 
Diabetes mellitus  53 (32)  30 (43)  .102 
Hypertension  118 (71)  55 (79)  .211 
Dyslipidemia  73 (44)  46 (66)  .002 
History of smoking  115 (69)  44 (63)  .369 
NYHA III-IV  53 (32)  46 (66)  <.001 
COPD  40 (27)  20 (31)  .557 
SBP, mmHg  126 ± 21  120 ± 22  .085 
LVEF, %  40 ± 17  41 ± 18  .651 
NT-proBNP, ng/L  2.968 ± 5.481  6.143 ± 7.679  .002 
GFR (CKD-EPI, mL/min/1.73 m2  62 ± 20  53 ± 19  .001 
Hemoglobin, g/L  134 ± 18  126 ± 18  .002 
β-blockers  146 (87)  56 (80)  .142 
ACEI/ARA-II  147 (88)  60 (86)  .626 
Furosemide  129 (77)  65 (93)  .004 
Aldosterone antagonists  75 (45)  38 (54)  .187 
Pacemaker  19 (13)  15 (23)  .057 
Resynchronization  13 (8)  8 (11)  .368 
ICD  29 (17)  14 (20)  .631 
Heart transplant  3 (2)  5 (7)  .038 
Signs of left HF  25 (15)  22 (31)  .004 
HR > 70 bpm  89 (53)  37 (53)  .951 
Anemia  51 (31)  36 (51)  .002 
NT-proBNP > 1000 ng/L  94 (56)  58 (83)  <.001 
GFR < 60 mL/min/1.73 m2  60 (36)  44 (63)  <.001 
LA > 26 mm/m2  77 (46)  44 (63)  .019 
Overall mortality, %  4 (2)  22 (31)  < .001 
Discrimination and calibration in the overall population  C statistic  P value: Hosmer-Lemershow  Slope  Intersection 
Readmission for HF at 1 mo  0.67  .458  0.54  −1.23 
Readmission for HF at 1 y  0.71  .601  1.05  0.05 

ACEI, angiotensin converting enzyme inhibitor; ARA-II, angiotensin II receptor antagonist; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; COPD, chronic obstructive pulmonary disease; GFR, glomerular filtration rate; HF, heart failure; HR, heart rate; ICD, implantable cardioverter device; LA, left atrium; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association functional class; SBP, systolic blood pressure.

Data are expressed as No. (%) or mean ± standard deviation.

The analysis of risk categories according to the Redin-SCORE obtained showed a progressive increase in the percentage of events, both at 1 month (< 20 points, 3.2%; ≥ 20 points, 9.4%; P = .04) and at 1 year (≤ 12 points, 12.2%; 13–20 points, 36%; 21–30 points, 47%; P < .001). Given the difference in recorded events between the derived population and the external validation population, the probabilities of different scores were recalibrated and nonsignificant values were obtained in the goodness-of-fit test (Table). In addition, the C statistics in the current cohort were not significantly different from the discrimination measures generated in our original series (C = 0.67 vs C = 0.73 at 1 month, P = .459; C = 0.71 vs C = 0.67 at 1 year, P = .295). In the external validation performed previously in the MUSIC cohort, values for a C index of 0.71 and 0.69 were obtained at 6 months and 1 year, respectively. The Figure shows the decision curves analysis, which shows that application of the Redin-SCORE improves the net benefit with respect to the strategy of not applying any discrimination to the population of patients with HF.


Decision curves for the Redin-SCORE model for predicting readmission for HF at 1 year. The x axis represents the probability threshold for readmission for HF according to the Redin-SCORE. The y axis represents the net benefit ([true positives - w x false positives] / total number of patients): positive values indicate an improvement in the classification of patients, and w is a correction factor for the probability threshold. The upper limit is 0.30 because the incidence of readmission for HF in study was 30%. The continuous red line indicates that no patient was readmitted for HF at 1 year. The blue line assumes that all expected patients were readmitted, 30% during the first year. The dotted line represents the result of applying the Redin-SCORE model. Thus, for a probability of readmission at 1 year of between 10% and 60%, the Redin-SCORE provides a net benefit due to better classification of the patients. HF, heart failure.


The present study provides external validation for the Redin-SCORE, a new scale for predicting short- and long-term readmission for HF in outpatients. In a contemporary cohort of patients with HF, the Redin-SCORE showed acceptable discriminatory capacity and calibration, particularly at 1 year. This study supports its clinical usefulness as a stratification tool for patients with HF in Spain.


Cooperative Health Research Thematic Networks of the Carlos III Health Institute (REDINSCOR) [no. RD06-0003-0000] and Cardiovascular Research Network of the Carlos III Health Institute (RIC) [no. RD12/0042/0002].

I. Sayago-Silva, F. García-López, J. Segovia-Cubero.
Epidemiología de la insuficiencia cardiaca en España en los últimos 20 años.
Rev Esp Cardiol., 66 (2013), pp. 649-656
J. Comín-Colet, J.M. Verdú-Rotellar, E. Vela, M. Clèries, M. Bustins, L. Mendoza, et al.
Eficacia de un programa integrado hospital-atención primaria para la insuficiencia cardiaca: análisis poblacional sobre 56.742 pacientes.
Rev Esp Cardiol., 67 (2014), pp. 283-293
L. Frankenstein, H. Fröhlich, J.G.F. Cleland.
Abordaje multidisciplinario en pacientes hospitalizados por insuficiencia cardiaca.
Rev Esp Cardiol., 68 (2015), pp. 885-891
J. Álvarez-García, A. Ferrero-Gregori, T. Puig, R. Vázquez, J. Delgado, D. Pascual-Figal, et al.
A simple validated method for predicting the risk of hospitalization for worsening of heart failure in ambulatory patients: the Redin-SCORE.
Eur J Heart Fail., 17 (2015), pp. 818-827
E.W. Steyerberg, Y. Vergouwe.
Towards better clinical prediction models: seven steps for development and an ABCD for validation.
Eur Heart J., 35 (2014), pp. 1925-1931
A.J. Vickers, E.B. Elkin.
Decision curve analysis: a novel method for evaluating prediction models.
Med Decis Making., 26 (2006), pp. 565-574
Copyright © 2016. Sociedad Española de Cardiología
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.